Acrivon Therapeutics, Inc. Common Stock (ACRV)
Automate Your Wheel Strategy on ACRV
With Tiblio's Option Bot, you can configure your own wheel strategy including ACRV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ACRV
- Rev/Share 0.0
- Book/Share 4.1822
- PB 0.263
- Debt/Equity 0.0219
- CurrentRatio 11.168
- ROIC -0.5674
- MktCap 34490898.0
- FreeCF/Share -1.8287
- PFCF -0.4918
- PE -0.5037
- Debt/Assets 0.0199
- DivYield 0
- ROE -0.4466
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | ACRV | Piper Sandler | -- | Overweight | -- | $6 | May 5, 2025 |
| Initiation | ACRV | KeyBanc Capital Markets | -- | Overweight | -- | -- | Jan. 31, 2025 |
| Upgrade | ACRV | Ladenburg Thalmann | Neutral | Buy | -- | $16 | Sept. 16, 2024 |
News
Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Acrivon Therapeutics, Inc. (ACRV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read More
Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV)
Published: April 14, 2025 by: Zacks Investment Research
Sentiment: Positive
The heavy selling pressure might have exhausted for Acrivon Therapeutics, Inc. (ACRV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
Acrivon Therapeutics, Inc. (ACRV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Read More
About Acrivon Therapeutics, Inc. Common Stock (ACRV)
- IPO Date 2022-11-15
- Website https://www.acrivon.com
- Industry Biotechnology
- CEO Dr. Peter Blume-Jensen M.D., Ph.D.
- Employees 75